Loramyc® obtains Marketing Authorization in Switzerland

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the
treatment and supportive care of cancer and AIDS patients, today announced that Loramyc® has obtained
Marketing Authorization in Switzerland for the treatment of oropharyngeal candidiasis in
immunocompromised patients (mainly cancer and AIDS patients with oral opportunistic infections).
“This approval represents an important milestone for Loramyc® which is now registered in 12 countries in
Europe, including Switzerland. This step will thus reinforce Loramyc® opportunity for a European
commercial agreement for which we are actively seeking a suitable partner involved in the supportive care
field”, said Dominique Costantini, President and CEO of BioAlliance Pharma.
“Loramyc® value has also recently been strengthened by the US FDA acceptance of its New Drug
Application“, added Dominique Costantini.

090824EN_Loramyc Suisse